PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28985259-4 2018 Warfarin use was associated with a non-significant increase in risk of major bleeding compared with no antithrombotic therapy (RR 1.26, 95% CI 0.99-1.52, I2 = 0.0%, n = 7) and aspirin (RR 1.20, 95% CI 0.91-1.50, I2 = 0.0%, n = 5). Warfarin 0-8 ribonucleotide reductase catalytic subunit M1 Homo sapiens 127-131 28655151-8 2018 Thromboembolism occurred in one patient (0.15%) receiving NOAC and in two patients (0.14%) receiving warfarin (risk ratio (RR) 1.07; 95% confidence interval (CI) 0.10-11.81). Warfarin 101-109 ribonucleotide reductase catalytic subunit M1 Homo sapiens 111-128 28985259-4 2018 Warfarin use was associated with a non-significant increase in risk of major bleeding compared with no antithrombotic therapy (RR 1.26, 95% CI 0.99-1.52, I2 = 0.0%, n = 7) and aspirin (RR 1.20, 95% CI 0.91-1.50, I2 = 0.0%, n = 5). Warfarin 0-8 ribonucleotide reductase catalytic subunit M1 Homo sapiens 185-189 26871818-6 2016 Pooling the results showed that warfarin use was associated with higher risk of any stroke (RR 1.50, 95% CI: 1.13-1.99). Warfarin 32-40 ribonucleotide reductase catalytic subunit M1 Homo sapiens 92-96 26871818-8 2016 Warfarin heightened overall bleeding risk (RR 1.27, 95% CI: 1.03-1.56), but not death (RR 0.67, 95% CI: 0.37-1.21).Among patients with atrial fibrillation undergoing hemodialysis, use of warfarin is associated with a higher risk of hemorrhagic stroke, but did not increase overall mortality. Warfarin 0-8 ribonucleotide reductase catalytic subunit M1 Homo sapiens 43-47